Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160362 | 0.79 | F2 (0.35) | NOTUMMGLLMAOBALDH1A1MAPT | |
| SCHEMBL17626275 | 0.79 | NOTUM (0.47) | NOTUMMGLLMAPTLMNARAB9A | |
| SCHEMBL4716988 | 0.79 | ENPP2 (0.47) | MGLLALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL1900336 | 0.75 | KDM4E (0.37) | NOTUMALDH1A1 | |
| SCHEMBL2096016 | 0.74 | CYP11B2 (0.36) | NOTUM | |
| SCHEMBL12841347 | 0.70 | CYP1A2 (0.52) | NOTUMMGLLALDH1A1MAPTLMNA | |
| SCHEMBL7160454 | 0.68 | ALKBH5 (0.39) | NOTUM | |
| SCHEMBL1895992 | 0.66 | NOTUM (0.49) | NOTUMALDH1A1MAPTHTTPKM | |
| SCHEMBL1897967 | 0.66 | HCAR1 (0.37) | TDP1HCAR1RAB9A | |
| SCHEMBL7162312 | 0.64 | RXRA (0.38) | NOTUMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503998-B1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | claimed |
| US-20070088063-A1 | Gamma-secretase inhibitors | CASTRO PINEIRO JOSE L | 2007-04-19 | — | — | US | claimed |
| US-20050143369-A1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2005-06-30 | — | — | US | claimed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-8222418-B2 | Piperidines and related compounds for the treatment of dementia | Merck Sharp + Dohme Corp. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2001848-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA | MERCK SHARP & DOHME (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| EP-2063710-B1 | DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2262499-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | University Health Network (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010069069-A1 | CATHEPSIN B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-06-24 | — | — | WO | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | NOTUM 3602/4885MGLL 2049/4885MAOA 527/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | NOTUM 2758/4885MGLL 4247/4885MAOA 2160/4885 |
| US-20070088063-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | NOTUM 954/4885MGLL 1895/4885MAOA 1944/4885 |
| US-20050143369-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | NOTUM 954/4885MGLL 1895/4885MAOA 1944/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | NOTUM 3993/4885MGLL 1900/4885MAOA 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.